Hydroxyfasudil Hydrochloride CAS: 155558-32-0
Hydroxyfasudil Hydrochloride is a cell permeable metabolite of HA 1077.

Hydroxyfasudil Hydrochloride (CAS 155558-32-0)

Hydroxyfasudil Hydrochloride | CAS 155558-32-0 is rated 5.0 out of 5 by 1.
  • y_2020, m_11, d_22, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202176, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 133ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: 1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine hydrochloride; HA-1100•hydrochloride
Application: Hydroxyfasudil Hydrochloride is a cell permeable metabolite of HA 1077
CAS Number: 155558-32-0
Molecular Weight: 343.8
Molecular Formula: C14H18ClN3O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

Hydroxyfasudil hydrochloride is a cell-permeable, hydroxylated metabolite of HA 1077 (Fasudil) that displays anti-anginal properties. Acts as an ATP-competitive and a reversible inhibitor of Rock (Rho-kinase) (IC50 = 0.9 and 1.8 μM using a peptide and MLC as substrate, respectively) with ~100-fold greater selectivity over MLCK, MRCKb, and PKC. Hydroxyfasudil hydrochloride is reported to inhibit the Rock (Rho kinase)-mediated contraction in vitro.


References

Ito, K., et al. 2003. J. Physiol. 546, 823. Takemoto, M., et al. 2002. Circulation 106, 57. Shimokawa, H., et al. 1999. Cardiovasc. Res. 43, 1029.

Usage :
Stock solutions are stable for up to one month when stored at -20°C. However it is recommended to prepare fresh solutions if possible.

After reconstitution, prepare aliquots and store at -20°C.
Appearance :
Crystalline powder
Physical State :
Solid
Solubility :
Soluble in aqueous acid, methanol (sparingly), and water (20 mM).
Storage :
Store at -20° C
Melting Point :
>250° C (dec.)
Boiling Point :
622.8° C at 760 mmHg (Predicted) (tautomer)
Refractive Index :
n20D ~1.61 (Predicted)
IC50 :
Rock-2: IC50 = 575.44 nM (human); Rock-1: IC50 = 758.58 nM (human); MCP-1: IC50 = 0.69 µM (human)
Ki Data :
Rock-1: Ki= 31.62 nM (human)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
HM3949000
PubChem CID :
11371328
MDL Number :
MFCD06411567
SMILES :
Cl.OC1=NC=CC2=C(C=CC=C12)S(=O)(=O)N1CCCNCC1

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Hydroxyfasudil Hydrochloride (CAS 155558-32-0)  Product Citations

See how others have used Hydroxyfasudil Hydrochloride (CAS 155558-32-0). Click on the entry to view the PubMed entry .

Citations 1 to 2 of 2 total

PMID: # 29344898  2018. Methods Mol. Biol. 1711: 351-398.

PMID: # 25172415  Kale, VP. et al. 2014. Cancer Lett. 354: 299-310.

Citations 1 to 2 of 2 total

Can you please provide the citation for the source of the following info in your product info: Rock-2: IC50 = 575.44 nM (human); Rock-1: IC50 = 758.58 nM (human)

Asked by: CELS
Thank you for your question. This information is derived from the following citations: Ito, K., et al. 2003. J. Physiol. 546, 823. Takemoto, M., et al. 2002. Circulation 106, 57. Shimokawa, H., et al. 1999. Cardiovasc. Res. 43, 1029.
Answered by: Technical Support
Date published: 2020-05-05

Is there any solvents appropriate for this chemical that have a low boiling point? 

Asked by: hawkeye11
Thank you for your question. This chemical, Hydroxyfasudil Hydrochloride: sc-202176 (CAS 155558-32-0), is soluble in methanol, which has a low boiling point and the solubility is ~1-2 mg/mL.
Answered by: Technical Support
Date published: 2016-12-13

Can you please provide details on how the info of your product: Rock-2: IC50 = 575.44 nM (human); Rock-1: IC50 = 758.58 nM (human) was dervived or calculated from these references: Ito 2003, Takemoto 2002, Shimokawa 1999? It is not clear in the papers.

Asked by: AVRL
  • y_2020, m_11, d_22, h_16CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_3
  • loc_en_US, sid_202176, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 127ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Holmstr m Holmstr m, F. et al. (PubMed 26286428) found that treatment with Hydroxyfasudil, a Rho kinase inhibitor, decreased the growth factors, inflammatory cytokines, and morphological abnormalities in spontaneously hypertensive rat ventral prostate. -SCBT Publication Review
Date published: 2015-07-18
  • y_2020, m_11, d_22, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202176, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 6ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.